News
Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...
Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials. Regeneron and Sanofi are assessing the data and will discuss next steps ...
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former smokers who have inadequately controlled chronic obstructive ...
TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational ...
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...
Treatment with itepekimab resulted in a lower incidence of events indicating loss of asthma control and improved lung function in adults with moderate to severe asthma, according to new phase 2 data.
TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results